Dr. Hope Rugo and advocate Jonise Louis discuss new ADCs, biomarker testing, and patient-centered dosing for metastatic triple-negative breast cancer. The treatment paradigm for metastatic ...
Wastewater — a sanitized name for human fecal matter and urine — tells the story, providing evidence even before the symptoms ...
Wellbeing Magazine on MSN
Optimizing sample throughput in large-scale NGS sequencing services
As demand for high-throughput genomic profiling continues to grow, laboratories and research organizations face increasing pressure to maximize sample throughput The post Optimizing Sample Throughput ...
CAMBRIDGE, England and MONTREAL, March 19, 2026 /PRNewswire/ -- CellCarta and Biofidelity today announce an expanded multi-year global strategic partnership, including exclusivity for Aspyre (R) Lung ...
For adults with acute myeloid leukemia (AML), pretransplant NPM1 measurable residual disease (MRD) is prognostic for relapse, according to a study recently published in Bone Marrow Transplantation.
As microbiome sequencing throughput increases, laboratories face growing pressure to maintain reproducible results while managing hands-on time, workflow complexity and costs. Many labs need ...
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the MyChoice ® CDx ...
Routine newborn screening (NBS) has transformed early disease detection. However, traditional biochemical tests limit the range of conditions that can be identified at birth. Next-generation ...
Tuberculosis (TB) is the world’s leading cause of death from a single infectious agent, affecting more than 10 million people each year and caused an | Genetics And Genomics ...
Routine newborn screening (NBS) has transformed early disease detection. However, traditional biochemical tests limit the range of conditions that ...
Understand the importance of targeted assays in personalised medicine and how early decisions shape clinical outcomes.
Early Detection The core patent related to Burning Rock's proprietary ultrasensitive detection technology, ELSA-seq (Patent No.: US 12460202 B2), has officially been granted by the United States ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results